鏈接全球制藥生態 共筑健康未來
Connecting the Global Pharmaceutical
Ecosystem, Building a Healthier Future Together
海南中和藥業閃耀 2025 德國法蘭克福 CPHI 原料藥展
Hainan Zhonghe Pharmaceutical Shines at CPHI Frankfurt 2025
2025年10月28日至30日，全球制藥行業的年度盛會 —— 世界制藥原料展覽會（CPHI Frankfurt 2025）在德國法蘭克福展覽中心盛大落幕。作為全球規模最大、影響力最廣的制藥專業展會，本屆盛會匯聚了來自 150 多個國家和地區的 2500 余家參展商及 45000 余名專業觀眾，成為洞察行業趨勢、鏈接全球資源的核心樞紐。
From October 28 to 30, 2025, the world’s leading pharmaceutical event — CPHI Frankfurt 2025 — successfully concluded at Messe Frankfurt, Germany. As the largest and most influential pharmaceutical exhibition globally, this year’s event brought together over 2,500 exhibitors and 45,000 professional visitors from more than 150 countries and regions, serving as a central hub for industry insights and global collaboration.
作為中國多肽藥物研發與生產的領軍企業，海南中和藥業股份有限公司（以下簡稱“海南中和藥業”）攜其領先的多肽產品線及國際化服務方案盛裝出席，與全球業界伙伴進行了深度交流，充分展示了其在多肽領域的生產能力與國際化戰略布局。
As a leading enterprise in peptide drug research, development, and manufacturing in China, Hainan Zhonghe Pharmaceutical Co., Ltd. made a grand appearance at the event, showcasing its cutting-edge peptide product portfolio and comprehensive international service solutions. The company engaged in in-depth exchanges with global industry partners, fully demonstrating its strong manufacturing capabilities and strategic international presence in the peptide field.
● 聚焦核心優勢，展示多肽技術硬核實力
● Highlighting Core Strengths, Showcasing the Power of Peptide Innovation
本次展會，海南中和藥業重點展示了公司在免疫、腫瘤、肝病、急救、消化、泌尿、婦科圍產等領域的核心原料藥產品矩陣，以及原料制劑一體化的產業優勢。公司憑借其在固相合成技術上的深厚積累，向國際客戶呈現了從克級到公斤級、從常規到復雜長鏈多肽的穩定、規模化生產能力。
At this exhibition, Hainan Zhonghe Pharmaceutical focused on showcasing its core API product portfolio across key therapeutic areas including immunology, oncology, hepatology, emergency medicine, gastroenterology, urology, and obstetrics & gynecology, as well as its integrated advantages in both API and finished dosage manufacturing. Leveraging its deep expertise in solid-phase synthesis technology, the company demonstrated to international clients its stable and scalable production capabilities, ranging from gram to kilogram levels and covering both conventional and complex long-chain peptides.
展會期間，海南中和藥業的展臺吸引了大量專業訪客駐足咨詢與洽談，我們通過產品展板、技術手冊、現場答疑等多種形式全方面推廣我們的核心成果。公司的商務團隊和技術專家與全球各地區的潛在客戶、合作伙伴就多肽藥物的研發趨勢、質量管控、產能保障和法規事務等議題進行了廣泛而深入的探討，并達成了多項初步合作意向。
During the exhibition, Hainan Zhonghe Pharmaceutical’s booth attracted a large number of professional visitors for consultations and business discussions. Through product displays, technical brochures, and on-site Q&A sessions, the company comprehensively showcased its core achievements and technological strengths. The business and technical teams engaged in extensive and in-depth exchanges with potential clients and partners from around the world on topics such as peptide drug R&D trends, quality management, production capacity assurance, and regulatory affairs, leading to the establishment of multiple preliminary cooperation intentions.
● 深化國際合作，共拓全球醫藥市場
● Forging International Collaborations to Explore Global Pharma Horizons
CPHI是全球制藥原料領域最重要的交流平臺。通過此次參展，我們不僅鞏固了與老客戶的信任關系，更結識了眾多志同道合的新伙伴。我們深切感受到全球市場對高質量、高性價比多肽藥物日益增長的需求。海南中和藥業將始終堅持 “立足中國、服務全球” 的發展理念，持續完善產業鏈布局，強化研發創新投入，推動產品與服務向更高質量、更寬領域、更深層次發展。
CPHI is the world’s most important platform for exchanges in the pharmaceutical API sector. Through our participation in this year’s exhibition, we not only strengthened trust with existing clients but also connected with many like-minded new partners. We deeply felt the growing global demand for high-quality, cost-effective peptide drugs. Hainan Zhonghe Pharmaceutical will continue to uphold its development philosophy of “Rooted in China, Serving the World”, steadily optimizing its industrial chain layout, enhancing investment in R&D and innovation, and promoting its products and services toward higher quality, broader scope, and deeper impact.
此次法蘭克福之行，是海南中和藥業推進國際化戰略的關鍵一步。通過面對面的交流，公司進一步了解了國際市場的動態與需求，也為未來拓展更廣闊的海外市場奠定了堅實的基礎。
This trip to Frankfurt marked a key step in Hainan Zhonghe Pharmaceutical’s internationalization strategy. Through face-to-face exchanges, the company gained a deeper understanding of international market dynamics and needs, laying a solid foundation for expanding its presence in global markets.
關于海南中和藥業股份有限公司
About Hainan Zhonghe Pharmaceutical Co., Ltd.
海南中和藥業股份有限公司（以下簡稱中和藥業）成立于1995年4月17日，是我國專業從事化學合成多肽藥物的研究和實現產業化的國家高新技術企業，中國國內化學合成多肽類新藥“注射用胸腺五肽”就由中和藥業自行研發上市，并在2003年“非典”疫情中發揮了重大作用，被海南省人民政府予以嘉獎。歷經近30年的發展，公司產品已涵蓋免疫、腫瘤、肝病、心血管、內分泌、婦科圍產等多個治療領域，并擁有多肽原料藥、化學原料藥及小容量注射劑（包括預灌封、卡式瓶）、凍干粉針劑、片劑、膠囊劑等多種劑型的生產能力，產品已成功出口韓國、烏茲別克斯坦、蒙古、巴基斯坦等多個國家和地區。
Hainan Zhonghe Pharmaceutical Co., Ltd. (hereinafter Zhonghe Pharmaceutical) was founded on April 17, 1995, and is a national high-tech enterprise in China specializing in the research and industrialization of chemically synthesized peptide drugs. The company independently developed and launched China’s first chemically synthesized peptide new drug, Thymopentin for Injection, which played a significant role during the SARS outbreak in 2003 and was recognized with an award by the Hainan Provincial Government. After nearly 30 years of development, Zhonghe Pharmaceutical’s products now cover multiple therapeutic areas, including immunology, oncology, hepatology, cardiovascular, endocrinology, and obstetrics & gynecology. The company has production capabilities for peptide APIs, chemical APIs, and various dosage forms, including small-volume injections (pre-filled and cartridge vials), lyophilized powders for injection, tablets, and capsules. Its products have been successfully exported to South Korea, Uzbekistan, Mongolia, Pakistan, and other countries and regions.
歡迎掃描二維碼，瀏覽我們的藥品、原料藥及化妝品產品目錄。
Scan the QR code to discover our range of pharmaceuticals, APIs, and cosmetics
孫經理 Director Sun:18078993802(國內) Domestic Department
唐經理 Director Tang:13876688684(國內) Domestic Department
TEL:0898-66802207(國際) International Department
E-mail: lizhongjing@zhonghe.cn(國際) International Department
